Drugs for depression are recalled in the US market by Sun Pharma subsidiary

17 Oct 2023 , 12:30 PM

Sun Pharma, an Indian pharmaceutical company, has recalled an antidepressant from American pharmacies.

Sun Pharmaceutical Industries Inc., a wholly-owned subsidiary of Sun Pharmaceutical Industries with headquarters in the US, voluntarily recalled the product. The US Food and Drug Administration said that the company recalled 144 bottles of bupropion hydrochloride extended-release tablets.

According to the daily US FDA Recall Information updates, the company voluntarily started the recall on October 4. All US states issued recalls for the medications.

‘Failed dissolving specifications’ were cited by the US authorities as the cause of this recall. Extended-release tablets of bupropion hydrochloride, USP (SR), are recommended for the treatment of major depressive disorder. Sun Pharmaceutical Industries Limited Halol-Baroda Highway, Gujarat, is where the product was made.

The US FDA categorized the recall as a Class-III recall. A Class-III recall, as defined by the US FDA, takes place when ‘use of, or exposure to, a violative product, is not likely to cause adverse health consequences.’

Sun Pharma has informed Indian stock markets that it anticipates publishing its FY 24 second-quarter earnings on November 1.  An import alert at Halol and supply disruptions from Mohali had a negative influence on Sun’s generic sales, according to a recent analysis by brokerage Nuvama on the Indian pharmaceutical industry.

At 10.18am on October 17, Sun Pharma shares were trading slightly higher on the NSE at Rs 1,140.25.

Calls and emails regarding the issue have gone unanswered by the company. Once the business responds, the copy will be changed.

For feedback and suggestions, write to us at [e-mail]